Dr. Yufang Hu received his B.S. in Pharmacy from Kaohsiung Medical University in Kaohsiung City, and his M.S. degrees and Ph.D. in Industrial Pharmacy from St. John’s University in New York City. He is a registered pharmacist as well. Before coming back to Taiwan, he had worked for the Bristol-Myers Squibb Pharmaceutical Company (New Jersey), Barr Laboratory (New Jersey), and the ImmuLogic Pharmaceutical Corporation (Boston). From 1999, he joined TTY Biopharm to build up a R&D Center from scratch, to currently include more than 60 scientists. More than 30 prescription drugs were launched through this center, including two liposomal injections. In addition, another two liposomal injections, and more four long-active depot injection products are presently under development. He has solicited and received substantial government grants for more than 3 million USD to support these two special drug delivery systems: liposome and depot injection plate forms. In 2017, he founded EnhanX Biopharm, Inc., a TTY subsidiary company, that focuses on developing special drug delivery systems.